Statutory Statements

Statutory Statements

The following statutory financial information of Assurant has been determined in conformity with statutory accounting practices ("SAP") prescribed or permitted by the Insurance Departments of the applicable state. SAP does not prescribe or permit consolidation. The results for past accounting periods are not necessarily indicative of results to be expected for any future accounting period. The Statutory Financial Statements were prepared in conformity with SAP, which principles differ in certain significant respects from accounting principles generally accepted in the United States of America ("GAAP").

Below are ten of the largest legal entities that represent the majority of Assurant's total statutory income. The attached files are fairly large in size, which may cause a delay in downloading the information.

Additional Financial Statements

The combined statutory net income, excluding intercompany dividends and surplus note interest, and capital and surplus of the Company’s U.S. domiciled statutory insurance subsidiaries is as follows:

Years Ended December 31,

2023 2022 2021
Property and Casualty ("P&C") companies $529.4 $283.5 $468.0
Life and Health ("L&H") companies 13.7 20.0 18.6
Total statutory net income (1) $543.1 $303.5 $486.6

(1)There was no statutory net income for the years ended December 31, 2022 and 2021 from the insurance entities included in the disposed Global Preneed business due to the August 2021 sale.

December 31,

2023 2022
P&C companies $1,461.4 $1,472.2
L&H companies 87.6 80.2
Total statutory capital and surplus(1)



(1)There was no statutory capital and surplus as of December 31, 2022 and 2021 from the insurance entities included in the disposed Global Preneed business.

The Company also has non-insurance subsidiaries and foreign insurance subsidiaries that are not subject to SAP. The statutory net income and statutory capital and surplus amounts presented above do not include non-insurance subsidiaries and foreign insurance subsidiaries in accordance with SAP.

Insurance enterprises are required by state insurance departments to adhere to minimum risk-based capital ("RBC") requirements developed by the NAIC. The Company's insurance subsidiaries expect to exceed minimum RBC requirements as of December 31, 2023. In addition, all of our rated insurances subsidiaries currently maintain an A.M. Best financial strength rating of A.

The payment of dividends to the Company by any of the Company’s regulated U.S domiciled insurance subsidiaries in excess of a certain amount (i.e., extraordinary dividends) must be approved by the subsidiary’s domiciliary jurisdiction department of insurance. Ordinary dividends, for which no regulatory approval is generally required, are limited to amounts determined by a formula, which varies by jurisdiction. The formula for the majority of the jurisdictions in which the Company’s subsidiaries are domiciled is based on the prior year’s statutory net income or 10% of the statutory surplus as of the end of the prior year. Some jurisdictions limit ordinary dividends to the greater of these two amounts, others limit them to the lesser of these two amounts and some jurisdictions exclude prior year realized capital gains from prior year net income in determining ordinary dividend capacity. Some jurisdictions have an additional stipulation that dividends may only be paid out of earned surplus. If insurance regulators determine that payment of an ordinary dividend or any other payments by the Company’s insurance subsidiaries to the Company (such as payments under a tax sharing agreement or payments for employee or other services) would be adverse to policyholders or creditors, the regulators may block such payments that would otherwise be permitted without prior approval. Based on the dividend restrictions under applicable laws and regulations, the maximum amount of dividends that the Company’s U.S domiciled insurance subsidiaries could pay to the Company in 2024 without regulatory approval is $592.4 million. No assurance can be given that there will not be further regulatory actions restricting the ability of the Company’s insurance subsidiaries to pay dividends.

Investor Contact

Sean Moshier

Vice President, Investor Relations

55 Broadway, Suite 2901

New York, NY 10006


Matt Cafarchio

Director, Investor Relations

55 Broadway, Suite 2901

New York, NY 10006